

IN THE UNITED STATES PATENT, AND TRADEMARK OFFICE

In re Application of:

van Leengoed et al.

Serial No.: 09/202,104

Filed: April 30, 1999

For: IL-6 AND IL-6 RECEPTOR DERIVED PEPTIDE HAVING IL-6 ANTAGONISTIC

OR AGONISTIC ACTIVITY

Examiner: D. Romeo

Group Art Unit: 1647

Attorney Docket No.: 3890US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: <u>EL740532457US</u>

Date of Deposit with USPS: __January 16, 2001_

Person making Deposit: ____ Daniel Thatcher

Statement under 37 C.F.R. §§ 1.821(f)& (g)

Commissioner for Patents Washington, D.C. 20231

Sir:

I, Jarett K. Abramson, an attorney registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:

1. The enclosed paper copy of the SEQUENCE LISTING, as well as the enclosed copy of the SEQUENCE LISTING in computer readable form (CRF), are in compliance with the requirements of 37 C.F.R. §§ 1.821 through 1.825.

- 2. The enclosed copy of the SEQUENCE LISTING in computer readable form (CRF) is believed to be identical to the paper copy of the SEQUENCE LISTING.
- 3. The enclosed paper copy of the SEQUENCE LISTING contains no new matter.

Respectfully submitted,

Jarett K. Abramson

Registration No. P-47,376 Attorney for Applicants

TRASK BRITT, PC

P. O. Box 2550

Salt Lake City, Utah 84110

Telephone: (801) 532-1922

Date: January 16, 2001

N:\2183\3890\Sequence listing statement 2.wpd

Application No.: <u>09202104</u>

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

N 1 6 2001	¥ √2057 37	1.This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
TRADEMARY		2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
		3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
1	*	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
1		 The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
		The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
		7. Other:
	Арр	plicant Must Provide:
, *,	×	A n initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
•		An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
		A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
	For	questions regarding compliance to these requirements, please contact:
	For Pate	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support (SIRA)
		Technical Assistance703-287-0200 To Purchase Patentin Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE